As an example, CARs of mesothelin scFv-CD3z and folate receptor alpha (FRα) scFv-CD28 have been introduced simultaneously, resulting in an improved tumor trafficking and reduction of toxicity [106]. This evidence concerns the gene FOLR1 and neoplasm.